ArticleBiology direct2025
IGF2 regulates proliferation, differentiation, and mitochondrial bioenergetics in human satellite cells.
Article in Biology direct, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Myogenic dysregulation underlies human tongue overgrowth in Beckwith-Wiedemann syndrome.iScience · 2026Article
- SLC25A12 mitigates mitochondrial dysfunction in myoblast senescence, and alleviates cuproptosis-related changes under copper stress.Biology direct · 2026Article
- Musculoskeletal disorders: does cuproptosis hold the key?Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Insulin-like growth factors (IGFs) are key regulators of the stem cell niche, playing critical roles in the proliferation and differentiation of stem cells into various lineages, including skeletal muscle. While IGF2 is known to influence muscle development, its specific effects and mechanisms in human skeletal muscle remain incompletely understood. In this study, we demonstrate that IGF2 is a key regulator of human satellite cell (huSC) proliferation, differentiation, and mitochondrial bioenergetics. Using primary huSCs cultured under defined myogenic conditions, we show that IGF2 significantly enhances myoblast proliferation and promotes differentiation via upregulation of myogenic regulatory factors and activation of the IGF1 receptor (IGF1R) pathway. Knockdown of endogenous IGF2 impaired these processes, while exogenous supplementation restored myogenic potential. Notably, IGF2 also improved mitochondrial function, evidenced by increased oxygen consumption rate, mitochondrial mass, oxidative phosphorylation protein expression, and intracellular ATP production. These effects were primarily mediated through IGF1R signaling, with IGF2R playing a modulatory role in regulating IGF2 availability. Our findings reveal that IGF2 not only initiates structural differentiation but also drives metabolic reprogramming in huSCs, highlighting its dual role in supporting muscle regeneration and energy homeostasis. These insights highlight IGF2 as a promising therapeutic target for muscle-wasting conditions such as muscular dystrophy and age-related sarcopenia and suggest its broader potential in regenerative medicine strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.